194 related articles for article (PubMed ID: 26815661)
1. Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.
Kanter M; Turan G; Usta C; Usta A; Esen HH; Tavlı L; Celik C; Demirkol Y; Kanter B
J Mol Histol; 2016 Apr; 47(2):145-52. PubMed ID: 26815661
[TBL] [Abstract][Full Text] [Related]
2. The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables.
Turan G; Usta CS; Usta A; Kanter M; Tavli L; Karacan M; Celik C; Eser M
J Mol Histol; 2014 Dec; 45(6):679-87. PubMed ID: 25106503
[TBL] [Abstract][Full Text] [Related]
3. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
5. [Expression and significance of Survivin and Smac in ovarian mucinous tumors].
Wang HX; Chen G; Li GL; Jiang YJ
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):387-90. PubMed ID: 21055155
[TBL] [Abstract][Full Text] [Related]
6. Survivin in ovary tumors.
Plewka D; Jakubiec-Bartnik B; Morek M; Bogunia E; Bienioszek M; Wolski H; Kotrych D; Dziekan K; Seremak-Mrozikiewicz A; Plewka A
Ginekol Pol; 2015 Jul; 86(7):525-30. PubMed ID: 26376531
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of nucleostemin expression and its correlation with cyclin D1 expression in malignant ovarian tumors.
Lin S; Yu HS
Int J Gynecol Cancer; 2011 Oct; 21(7):1166-71. PubMed ID: 21892090
[TBL] [Abstract][Full Text] [Related]
9. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
10. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
11. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
[TBL] [Abstract][Full Text] [Related]
13. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
14. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
15. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression.
Iida T; Yasuda M; Miyazawa M; Fujita M; Osamura RY; Hirasawa T; Muramatsu T; Murakami M; Saito K; Mikami M
Arch Gynecol Obstet; 2008 Jun; 277(6):539-46. PubMed ID: 18026974
[TBL] [Abstract][Full Text] [Related]
16. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma.
Qian X; Xi X; Li L
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):126-32. PubMed ID: 20724919
[TBL] [Abstract][Full Text] [Related]
17. Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.
Hasby EA
Pathol Oncol Res; 2012 Apr; 18(2):509-18. PubMed ID: 22161157
[TBL] [Abstract][Full Text] [Related]
18. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
20. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
